Norgine enters into a new partnership with Adacyte Therapeutics to commercialise ADACOLUMN® in Switzerland

Back to media releases
Next media release
06 March 2019

CORPORATE MEDIA RELEASE

NORGINE ENTERS INTO A NEW PARTNERSHIP WITH ADACYTE THERAPEUTICS TO COMMERCIALISE ADACOLUMN® IN SWITZERLAND

 

Amsterdam, Wednesday 6 March, 10.00 CET. Norgine B.V. today announced that it has entered into a new partnership with Adacyte Therapeutics S.L. to exclusively distribute ADACOLUMN® in Switzerland.

ADACOLUMN® is a Class IIb CE marked medical device used as a treatment for steroid-dependant and steroid refractory moderate to severe inflammatory bowel disease (IBD).

Inflammatory bowel disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of the digestive tract. Types of IBD include ulcerative colitis (UC) and Crohn’s disease (CD). Both UC and CD usually involve severe diarrhoea, abdominal pain, rectal bleeding, fatigue and weight loss. IBD can be debilitating and sometimes leads to life-threatening complications.[i]

Peter Martin, Chief Operating Officer at Norgine said: “We are delighted to enter into our new collaboration with Adacyte. ADACOLUMN® provides an important alternative treatment option for patients who suffer from IBD.”

Antoni Villaró,  Chief Executive Officer  of Adacyte said: “As an established leader in providing innovative gastroenterology disease solutions to patients in Europe, Norgine is an excellent partner for Adacyte and ADACOLUMN®. Norgine´s commercial track record across Europe demonstrates their ability to achieve commercial success in Switzerland and will enable the patients suffering with moderate-severe inflammatory bowel disease to receive the benefits of ADACOLUMN®.”

Norgine anticipates launching ADACOLUMN® in Switzerland in the 2nd quarter of 2019.  

 

Notes to Editors:

About Norgine

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net sales were EUR 345 million, up 17 per cent.

Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply. Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

Norgine is headquartered in the Netherlands.

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

About Adacyte Therapeutics

Adacyte Therapeutics is a specialty therapeutic medical device company focused on the development and commercialization of innovative therapies for the treatment of difficult-to -treat autoimmune diseases mainly focused in Inflammatory Bowel Diseases. Adacyte’s lead product is ADACOLUMN®, a unique medical device system for selective leucocyte apheresis. Adacyte is a company headquartered in Barcelona, Spain and is the exclusive partner of Japan Immunoresearch Laboratories Company Limited (JIMRO) in Europe.

 

ABOUT ADACOLUMN®  

Inflammatory Bowel Disease is living a new era of treatment thanks to the introduction of biologic therapy. There is, however, an urgent need for therapies for steroid-dependent and steroid refractory moderate-to-severe active Inflammatory Bowel Disease patients due to side effects, patient intolerance to existing treatments and failure of previous treatments. After the failure of existing therapies, surgery is often the only remaining option. In this context, ADACOLUMN®, a Granulocyte-Monocyte Adsorptive Apheresis, is an important non-pharmacological treatment with very few side effects. ADACOLUMN®  is currently available in Europe (Germany, UK, France, Italy, Spain, Sweden, Norway, Denmark, Finland, Iceland), Japan and China.

 

Media Contacts:

For Norgine:

Eleni Fistikaki +44 (0)1895826227 or +44 (0)7825 389477

Clara Bentham +44 (0)1895 826654 or +44 (0)7734 367883

contact@norgine.com

Follow us on twitter @norgine

For Adacyte:

Antoni Villaró, CEO, +34 618234445

Contact  a.villaro@adacyte.com

[i] Crohn’s & Colitis Foundation. Diagnosing and managing IBD. 2017; 1–37. Available at: http://www.ccfa.org/assets/pdfs/diagnosing-and-managing-ibd.pdf (Accessed March 2019).

Norgine Australia
Cookie Policy

Last update: 1 August 2023

 

What are cookies?

Cookies are small data files that websites download to a user’s computer, phone or tablet. Most web browsers automatically accept cookies. They help website providers, for example, to recognise a user that has visited a website previously. Further details on the cookies used on this Website and their purposes are set out below.

 

  • Helping you navigate the Website in the most easy way possible
  • Assisting in registering for our events, login and your ability to provide feedback
  • Analysing site usage (how many users visited a specific page for example)
  • Analysing the use of our products, services or applications
  • Assisting with our promotional and marketing efforts (including behavioural advertising)
  • Offering content of third parties (such as social media content)

 

Detailed information about each cookie can be found in the appropriate cookie category section of the banner as well as in the section below.

Cookie Category Description

STRICTLY NECESSARY COOKIES

The strictly necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You may be able to decline these cookies through your browser, but necessary parts of the site will not then work. These cookies do not store any personally identifiable information.

 

Detailed list of Strictly Necessary Cookies

First- and Third-party Cookies Name Provider Purpose Retention
Third Party moove_gdpr_popup mooveagency.com Records cookie settings. For user preferences only. No external interaction 1 year

 

FUNCTIONAL COOKIES

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

 

Detailed list of Functional Cookies

First- and Third-party Cookies Name Provider Purpose Retention
Not applicable        

 

PERFORMANCE COOKIES

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.

 

Detailed list of Performance Cookies

First- and Third-party Cookies Name Provider Purpose Retention
Third Party _ga_ google.com Record visitors cookie choice. 400 days
Third Party _gat_gtag_ google.com Records tracking code data 1 minute
Third Party _ga google.com Calculates visitor, session and campaign data and also keeps track of site usage. 400 days
Third Party _gid google.com Registers a unique ID that is used to generate statistical data on how the visitor uses the website. 1 day

 

MARKETING COOKIES

These cookies are used to track our visitors’ browsing habits. They can be used to build up a profile of search and/or browsing history for every visitor. Identifiable or unique data is collected to show relevant/personalized marketing content to each user. The information that uniquely identifies users’ browsers and internet devices is used to display targeted advertising and/or share this data with third parties for the same purpose.

 

Detailed list of Marketing Cookies

First- and Third-party Cookies Name Provider Purpose Retention
Not applicable        

 

Refusing cookies

You do not have to accept cookies, but without accepting them you may experience reduced Site functionality. You can manage your preferences regarding cookies and other tracking technologies and revoke your consent in the banner. You can withdraw your consent at any time. If you would like more information about deleting, disabling and blocking cookies, please visit the website: https://knowcookies.com and check the “manage cookies” and “webmasters guide” sections.

 

Updating our Cookie Policy

There is a possibility that we will update our cookie policy on this website in accordance with legal and technical requirements, therefore we recommend that you read this policy occasionally so that you are adequately informed about how and for what we use cookies.

 

Contact

If you have any questions about this Cookie Policy or the collection, processing and disclosure of your personal data and your data protection rights, please see our Privacy Policy.